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Patientsexperiencing lowerbody pain resulting from bonemetastaseshavegreater levelsof functionalinterference thanthosewith
upper body pain.The purpose ofthisstudy wasto assessthe levelsofinterference caused by painafter treatment withconventional
radiotherapy using the Brief Pain Inventory (BPI) and to validate this tool for telephone use. After radiotherapy, a total of 159,
129, and 106 patients completed the BPI over the telephone at months 1, 2, and 3, respectively. Cronbach’s alpha, conﬁrmatory
factor analysis, and discriminant validity tests were performed to assess the validity of the BPI. One-way ANOVA was used to
compare BPI scores. There was no statistically signiﬁcant diﬀerence in functional interference among patients after treatment.
Internal consistencyof the BPIwas high. Functional interference may be inherently higher in patients with pain in the lower body.
Telephone use of the BPI is reliable and recommended in this population.
1.Introduction
Bone metastases can occur in up to 70% of patients with
advanced cancer [1], and the resulting pain can lead to
an overall decrease in quality of life [2–5]. Conventional
externalbeamradiotherapyis acommontreatment modality
for bone metastases, and its eﬃcacy is well established [3].
Other treatments can include analgesic therapy, orthopedic
interventions (such as minimally invasive procedures and
surgery), radionuclides, systemic therapies, and stereotactic
body radiotherapy [6].
Bone metastases have received much attention in the
literature regarding eﬀective treatments and management of
pain resulting from the disease [1, 7–9]. The characterization
of other functional aspects such as pain interference (that
withwalking,sleep,andwork)hasbeenreportedlessthough.
Since the goal of treatment for bone metastases is mostly
palliative, functional interference is an important factor
which must be considered when assessing the quality of life
(QoL) for these patients.
The Brief Pain Inventory (BPI), developed by Cleeland
and Ryan [10], has been validated for use in advanced
cancer patients to assess pain and functional interference
stemming from bone metastases [11]. It was reported that
prior to treatment, patients with lower body bone metastases
experience greater levels of functional interference than
those with upper body metastases using the BPI [11]. The
characterization of functional interference in patients with
painful bone metastases is important for the management
and treatment of these patients and could help especially
with the prioritization of treatments. The purpose of this
study was toreportthepatterns ofpain andinterference after
treatment with conventional external beam radiotherapy,
and determine if upper and lower skeletal index sites
continue to demonstrate diﬀerent interference levels.
The BPI is usually administered to patients prior to
treatment in person. When following palliative patients, it is
beneﬁcial to reduce their number of visits to a health care
centre. Studies in the past [12–15] have usually collected
follow-up data across the telephone although this strategy2 Pain Research and Treatment
has not been validated. Therefore, our secondary objective
was to validate the BPI in patients with bone metastases
receiving conventional radiotherapy using the telephone
follow-up method.
2.Methods
2.1. Demographics. The Rapid Response Radiotherapy Pro-
gram (RRRP) at the Odette Cancer Centre, Toronto, Canada
provides rapid access to palliative radiotherapy. During the
period lasting from May 2003 to June 2007, patients with
bone metastases referred to the RRRP and subsequently
treated with palliative radiotherapy were screened for eligi-
bility for this prospective study assessing pain and functional
interference using the Brief Pain Inventory (BPI). The
institution’s research ethics board had approved this study
prior to commencement. Baseline data was collected, and
patients were followed at four-week intervals following the
end of radiotherapy for a total of 12 weeks (three followups
in total). Patients were contacted by telephone for these
followups by a trained research assistant. The BPI questions
were read out loud, and the patient did not have a physical
copy present when answering the items.
2.2. The Brief Pain Inventory (BPI). The BPI is a validated
multidimensional pain assessment tool developed by Clee-
land and Ryan [10] which is often used to assess pain
caused by bone metastases. It has been translated into many
languages and satisﬁes two recommendations (assessment of
pain to include both intensity and interference) set by the
Initiative on Methods, Measurements, and Pain Assessment
in Clinical Trials (IMMPACT) group [16]. Recently, research
has suggested that a three-factor analysis (pain, aﬀect inter-
ference,andactivity interference) couldyieldstronger results
while satisfying an additional IMMPACT recommendation
[11].
Three questions regarding pain intensity and seven
regarding pain interference are rated on an ordinal numer-
ical scale with anchors of 0 (no pain/interference) to 10
(maximum pain/interference). Pain intensity is measured
according to the worst pain experienced in the last three
days, average pain in the last three days, and current pain.
Pain interference assesses how that pain has aﬀected general
activity, mood, walking ability, normal work, relations with
others, sleep, and enjoyment of life.
2.3. Statistical Analysis. Demographic results were expressed
as means, standard deviations (SD), medians and interquar-
tiles for continuous variables, and proportion for categorical
values. Patients with complete data (no missing items on
the BPI) were used for analysis. All analyses were repeated
at all three follow-up intervals where data was collected. All
analyses (one-, two-, and three-factor) were used to validate
the psychometric properties of the BPI.
2.4. Analysis of Upper and Lower Skeletal Pain. Patients were
separated into groups based on the location of pain: upper
or lower skeletal metastases. Upper pain included patients
receiving treatment to cervical or thoracic spine, shoulder
girdle/upper extremity, ribs, and skull. Those receiving
treatment to the lumbar spine, sacrum, or any of the
pelvic girdle (iliac wing, acetabulum, pubic bone, ischial
tuberosity), femur (head, neck, or shaft), and tibia were
classiﬁed as having “lower skeletal pain”. Those receiving
treatment to the thoracolumbar spine were excluded from
this portion of theanalysis to preventinaccurate reporting of
pain location. One-way ANOVA was applied for comparing
mean scores of BPI subscales in patients with lower or with
upper skeletal bone metastases at diﬀerent follow-ups and
also at baseline.
2.5. Item Analysis and Internal Consistency. With two- and
three-factor analysis, item-item correlations were examined
to identify redundant questions. Standardized Cronbach’s
alpha was applied to estimate internal consistency within
each subscale [17]. Changes in the Cronbach’s alpha were
determinedbyremovingindividualitems.Decreasesinalpha
after removal mean strong correlation with other items
whereas increases describe weak correlation meaning the
removal makes the construct more reliable.
2.6. Conﬁrmatory Factor Analysis (CFA). CFA was used to
examine the structure of the BPI as a single construct (one-
factor, null 10-itemBPImodel,with all itemsincluded),two-
factor (pain and interference), and three-factor model (pain,
aﬀect,activity)foreachfollow-upperiod(4,8,and12weeks)
[18]. Covariance terms for the two-factor and three-factor
models were generated and repeated with the removal of
the sleep item [11]. Models were compared using various
model-ﬁt statistics [19] including (1) adjusted goodness of
ﬁt index (perfect ﬁt = 1), (2) Chi-square statistic, which
represents the value of the statistical criterion minimized
in maximum likelihood estimation (smaller value = better
ﬁt), (3) root mean square error of approximation (RMSEA)
with 90% upper level of conﬁdence intervals, measuring
the lack of ﬁt of the model to the population covariance
matrix (RMSEA ≥ 0.10 suggests poor ﬁt), (4) Bentler’s
comparative ﬁt index (CFI) and nonnormed ﬁt index
(NNFI), which measures the improvement in the overall ﬁt
and model complexity (above 0.9 suggests acceptable model
ﬁt).
Standardized factor loadings, associated statistics (i.e.,
R-squared and t-statistic), and composite reliability were
provided for the best two-factor and three-factor models.
Composite reliability is a measure of the overall reliability
of a collection of heterogeneous but similar items. The
minimum acceptance level of composite reliability is 0.70,
and the minimum critical t value is 3.29 for P = .001.
Discriminant validity tests (Chi-square diﬀerence test,
conﬁdence interval test, and variance extracted test) were
carried out to further evaluate highly correlated factors
within the three-factor model. The variance extracted esti-
mates the amount of variance that is explained by an
underlying factor in relation to the amount of variance due
to measurement error. Fornell and Larcker suggested that
constructs should exhibit estimates of 0.50 or larger [20].Pain Research and Treatment 3
Table 1: Patient demographics at weeks 4, 8, and 12 (with complete data sets).
Demographics Week 4 Week 8 Week 12
Age (year)
n 159 129 106
Mean ± SD 63.8 ± 13.1 63.9 ± 13.5 63.4 ± 13.8
Interquartiles 54–74 54–74 54–74
Median (Range) 65 (30–89) 66 (30–88) 64 (30–88)
Karnofsky performance status (KPS)
n 151 124 104
Mean ± SD 71.9 ± 13.1 72.6 ± 11.8 72.5 ± 12.5
Interquartiles 60–80 70–80 70–80
Median (range) 70 (30–90) 70 (40–90) 70 (40–90)
Worst pain
n 159 129 106
Mean ± SD 5.13 ± 2.67 4.84 ± 2.58 4.75 ± 2.44
Interquartiles 3–7 3–7 3–7
Median (range) 5.0 (1–10) 5.0 (1–10) 4.0 (1–10)
Average pain
n 159 129 106
Mean ± SD 3.57 ± 2.28 3.60 ± 2.20 3.33 ± 2.12
Interquartiles 2–5 2–5 2–5
Median (range) 3.0 (0–10) 3.0 (0–9) 3.0 (0–9)
Current pain
n 159 129 106
Mean ± SD 2.69 ± 2.49 2.33 ± 2.26 2.41 ± 2.37
Interquartiles 0–4 0–4 0–4
Median (range) 3.0 (0–10) 2.0 (0–10) 2.0 (0–9)
Total daily morphine equivalent (mg)
n 143 115 94
Mean ± SD 101.4 ± 162.5 91.6 ± 133.2 119.6 ± 194.5
Interquartiles 0–135 0–135 0–210
Median (range) 30 (0–904) 32 (0–832) 24 (0–1080)
Gender
Male 88 (55.35%) 70 (54.26%) 62 (58.49%)
Female 71 (44.65%) 59 (45.74%) 44 (41.51%)
Pain site
Lower limb 94 (59.12%) 76 (58.91%) 74 (69.81%)
Upper limb 63 (39.62%) 50 (38.76%) 29 (27.36%)
Other 2 (1.26%) 3 (2.33%) 3 (2.83%)
Primary cancer site
Prostate 46 (28.93%) 41 (31.78%) 32 (30.19%)
Breast 37 (23.27%) 31 (24.03%) 28 (26.42%)
Lung 41 (25.79%) 28 (21.71%) 24 (22.64%)
Bladder 10 (6.29%) 8 (6.20%) 6 (5.66%)
Pancreas/gastric 5 (3.14%) 0 (0.00%) 1 (0.94%)
Others 20 (12.58%) 37 (17.5%) 15 (14.15%)
Dose fractionation
Single 100 (62.89%) 72 (55.81%) 67 (63.21%)
Multiple 59 (37.11%) 57 (44.19%) 39 (36.79%)4 Pain Research and Treatment
Table 2: One-way ANOVA comparing upper versus lower skeletal pain at 4, 8, and 12 weeks posttreatment.
Subscales Lower skeletal pain Upper skeletal pain Mean diﬀerence (95% CI)
Mean SD Mean SD P value
At week 4 n = 94 n = 63
Mean pain 3.87 2.25 3.68 2.23 .6110 0.19 (−0.54–0.91)
Mean activity 5.12 3.22 4.79 3.24 .5347 0.33 (−0.71–1.36)
Mean aﬀect 3.52 2.79 3.96 3.24 .3645 0.44 (−0.52–1.40)
At week 8 n = 76 n = 50
Mean pain 3.69 2.13 3.42 1.96 .4765 0.27 (−0.48–1.01)
Mean activity 4.63 3.37 3.57 2.92 .0730 1.05 (−0.10–2.21)
Mean aﬀect 3.39 2.77 2.98 2.66 .4153 0.41 (−0.58–1.39)
At week 12 n = 74 n = 29
Mean pain 3.22 1.93 4.23 2.37 .0278 1.01(0.11–1.91)
Mean activity 4.22 3.09 4.45 3.45 .7460 0.23 (−1.16–1.62)
Mean aﬀect 2.58 2.33 2.99 2.73 .4437 0.41 (−0.65–1.47)
There is no signiﬁcant diﬀerence in functional interference (both activity and aﬀect—three-factor analysis) between upper and lower skeletal pain groups
after radiation. Mean pain is signiﬁcantlygreater at 12 weeks for the upper skeletalpain group (P = .0278).
It should be noted that Hatcher [18] cautions that the
variance-extracted estimate test is conservative; reliabilities
canbe acceptableevenifvariance-extracted estimates are less
than 0.50.
All analyses were performed using Statistical Analysis
System (SAS version 9.2 for Windows) software. Conﬁrma-
tory factor modeling was carried out using SAS covariance
analysisoflinearstructuralequations(PROCCALIS).Atwo-
sided P value of less than .05 was considered as statistically
signiﬁcant.
3.Results
3.1. Patient Characteristics. A total of 212, 159, and 133
patients at weeks 4, 8, and 12, respectively, had atleast partial
data. Of these patients, 159 (75%), 129 (81%), and 106
(80%) had complete data at weeks 4, 8, and 12, respectively,
and this cohort formed the study population for analyses on
pain and interference. Of the study population at week 4,
median age was 65 (range: 30–89), 88 of patients (55%) were
male, and 94 patients (60%) were classiﬁed as having lower
body pain (Table 1). At week 8, median age was 66 (range:
30–88), 70 (54%) of patients were male, and 76 patients
were classiﬁed as having lower body pain. Finally, at week 12,
median age was 64 (range: 30–88), 62 (58%) of patients were
male,and74patientshadlowerbodypain.Twopatientswere
excluded for having treatment to the thoracolumbar spine.
The most commonly missed item was normal work with 36
patientsmissing thisvalueat 4 weeksand 19 patientsmissing
this score for both weeks 8 and 12.
3.2. Pattern of Pain, Activity, and Aﬀect Interference in Lower
versus Upper Skeletal Pain at Follow-up. Analysis of baseline
data showed that patients with lower skeletal pain had
signiﬁcantly greater activity interference than those with
upper skeletal pain; this is similar to the result obtained
by Wu et al. [11] in their previous study. Analysis after
treatment with conventional radiotherapy showed that there
was no signiﬁcant diﬀerence in pain or interference scores
for lower and upper skeletal pain sites at 4 and 8 weeks
(Table 2). At week 4, mean values for pain, activity, and
aﬀect inpatientswith lowerskeletal painwere 3.87,5.12,and
3.52, respectively, in comparison to 3.68, 4.79, and 3.96 for
those with upper skeletal pain (all P values not statistically
signiﬁcant). At week 8, mean values for pain, activity, and
aﬀect in patients with lower skeletal pain were 3.69, 4.63,
and 3.39, respectively, in comparison to 3.42, 3.57, and
2.98 for those with upper skeletal pain (all P values not
statistically signiﬁcant). At 12 weeks posttreatment, pain was
signiﬁcantly worse for patients with upper skeletal pain than
those with lower skeletal pain (P = .0278), but interference
levels (both activity and aﬀect) were similar.
3.3.ItemAnalysisandInternal ConsistencyofSubscales. There
was internal consistency among all items except sleep at each
follow-up period. Improvement in correlation was seen at
each follow-up period and in both two- and three-factor
subscales when the sleep item was improved. Alpha for two-
factor analysis improved from 0.48 to 0.91 at 4 weeks, 0.54
to 0.91 at 8 weeks, and ﬁnally, 0.56 to 0.91 at 12 weeks. For
the three-factor analysis, removal of sleep from the activity
subscale improved alpha from 0.45 to 0.87 at 4 weeks, 0.48 to
0 . 9 0a t8w e e k s ,a n d0 . 5 3t o0 . 9 0a t1 2w e e k s( Table 3). In all
cases, removal of sleep indicated a more reliable construct.
3.4. Conﬁrmatory Factor Analysis. In general, both the two-
factor and the three-factor models demonstrated reasonably
high levels of internal consistency, composite reliability,
and convergent validity (Tables 4 and 5). The null model
(one-factor) demonstrated the worst ﬁt of the three; this was
expected given the well-established two-factor solution to
the BPI. The two-factor analysis performed poorly, however,
better than the null model; the three-factor model had the
best performance. For the two- and three-factor analyses,
considerable improvement in ﬁt was seen by removing
the sleep item and also by allowing speciﬁc error terms toPain Research and Treatment 5
Table 3: BPI internal consistency using Cronbach’s alpha.
Standardized Cronbach’s alpha
Item statistics Two subscales Three subscales
BPI items Mean SD Correlation with total Alpha with item deleted Correlation with total Alpha with item deleted
At week 4
Pain subscale (alpha = 0.88) Pain subscale (alpha = 0.88)
Worst pain 5.1 2.7 0.75 0.85 0.75 0.85
Average pain 3.6 2.3 0.83 0.78 0.83 0.78
Current pain 2.7 2.5 0.74 0.86 0.74 0.86
Interference subscale (alpha = 0.90) Activity subscale (alpha = 0.83)
General activity 5.1 3.4 0.79 0.87 0.78 0.72
Walking ability 4.5 3.5 0.71 0.88 0.66 0.78
Normal work 5.6 3.9 0.75 0.88 0.74 0.74
Sleep 3.2 3.4 0.48 0.91 ↑ 0.45 0.87 ↑
Aﬀect subscale (alpha = 0.84)
Mood 3.7 3.6 0.72 0.88 0.77 0.72
Enjoyment of life 5.0 3.4 0.79 0.87 0.66 0.83
Relations 2.5 3.3 0.67 0.89 0.70 0.79
At week 8
Pain subscale (alpha = 0.86) Pain subscale (alpha = 0.86)
Worst pain 4.8 2.6 0.75 0.78 0.75 0.78
Average pain 3.6 2.2 0.84 0.70 0.84 0.70
Current pain 2.3 2.3 0.62 0.91 0.62 0.91
Interference subscale (alpha = 0.91) Activity subscale (alpha = 0.85)
General activity 4.4 3.3 0.78 0.88 0.77 0.78
Walking ability 4.0 3.6 0.75 0.89 0.75 0.79
Normal work 4.5 3.8 0.80 0.88 0.79 0.77
Sleep 2.5 2.8 0.54 0.91 ↑ 0.48 0.90 ↑
Aﬀect subscale (alpha = 0.83)
Mood 3.4 3.2 0.80 0.88 0.76 0.71
Enjoyment of life 4.2 3.3 0.73 0.89 0.67 0.80
Relations 2.3 3.1 0.64 0.90 0.67 0.80
At week 12
Pain subscale (alpha = 0.88) Pain subscale (alpha = 0.88)
Worst pain 4.7 2.4 0.76 0.85 0.76 0.85
Average pain 3.3 2.1 0.85 0.76 0.85 0.76
Current pain 2.4 2.4 0.71 0.88 0.71 0.88
Interference subscale (alpha = 0.90) Activity subscale (alpha = 0.86)
General activity 4.5 3.3 0.80 0.88 0.78 0.80
Walking ability 3.9 3.5 0.77 0.88 0.77 0.80
Normal work 4.4 3.8 0.78 0.88 0.79 0.80
Sleep 2.8 3.2 0.56 0.91 ↑ 0.53 0.90 ↑
Aﬀect subscale (alpha = 0.82)
Mood 2.9 2.8 0.70 0.89 0.69 0.72
Enjoyment of life 3.4 3.0 0.77 0.88 0.72 0.70
Relations 2.0 2.9 0.64 0.90 0.60 0.82
A marked improvement was seen across all follow-up periods when the sleep item was removed from the BPI analysis.
covary. This result was seen at 4 weeks, 8 weeks, and 12
weeks posttreatment.
Factor loading and associate statistics for the best two-
factor and three-factor analyses were constructed at each
follow-up period. The correlation between grouped items
(e.g., pain, activity, and aﬀect in three-factor analysis) was
h i g hf o ra l lt h r e ed a t as e t s( Table 6 shows week 4 as an
example). At each follow-up period, there was a stronger
correlation between activity and aﬀect, which could be
indicative of the same latent variable.6 Pain Research and Treatment
Table 4: Model-ﬁt statistics for two-factor analysis and improvement after sleep removal at weeks 4, 8, and 12.
Model Modiﬁcation
Goodness of ﬁt
index
(adjusted)
Chi-square
(df)
RMSEA
(upper CL)
Comparative
ﬁt index
Nonnormed
ﬁt index
Model ﬁt statistics at week 4
2 factors: pain and
interference
Covary error terms of average-pain-
current pain, mood-relations, mood-
enjoyment, relations-enjoyment
0.95 47.1 (28) 0.07 (0.10) 0.98 0.97
2 factors: pain and
interference
Drop sleep: Covary error terms of
average-pain-current pain, mood-re-
lations, mood-enjoy-ment, relations-
enjoyment
0.97 26.3(20) 0.04(0.09) 0.99 0.99
Model ﬁt statistics at week 8
2 factors: pain and
interference
Covary error terms of average-pain-
current pain, mood-relations, mood-
enjoyment, relations-enjoyment
0.95 34.5 (28) 0.04 (0.08) 0.99 0.99
2 factors: pain and
interference
Drop sleep; covary error terms of
average pain-current pain, mood-re-
lations, mood-enjoyment, relations-
enjoyment
0.96 25.2(20) 0.05(0.09) 0.99 0.99
Model ﬁt statistics at week 12
2 factors: pain and
interference
Covary error terms of average-pain-
current pain, mood-relations, mood-
enjoyment, relations-enjoyment
0.92 46.2 (28) 0.08 (0.12) 0.97 0.96
2 factors: pain and
interference
Drop sleep; covary error terms of
average-pain-current pain, mood-re-
lations, mood-enjoy-ment, relations-
enjoyment
0.94 33.3(20) 0.08(0.13) 0.98 0.96
Acceptable model ﬁt Perfect ﬁt = 1 Smaller value RMSEA < 0.10 >0.90 >0.90
Model ﬁt statisticswere all improved after dropping sleep, at all time periods for two-factor analysis.
3.5. Discriminant Validity Tests for Evaluating Activity and
Aﬀect Factors. Discriminant validity tests provided mixed
supportforactivity andaﬀectatweeks4,8,and 12.Although
the conﬁdence interval (CI) test indicated correlation of
0.88, 0.87, and 0.85 at weeks 4, 8, and 12, respectively, (all
within the 95% CI at each period), the Chi-square diﬀerence
test demonstrated signiﬁcance between mixed and separated
support at all followups. The variance-extracted test failed
to conﬁrm discriminant validity for all three sets of data.
Despite these results, the combination of diﬀerent analyses
conﬁrmed the validity of the construct since reasonably
high levels of internal consistency, composite reliability, and
convergent validity were present at weeks 4, 8, and 12.
Although the two-factor model is adequate, the three-
factor model is preferred since fewer covariance terms were
needed to ﬁt the model. Furthermore, this model satisﬁes an
additional IMMPACT recommendation.
4.Discussion
Functional interference is a signiﬁcant component of qual-
ity of life in advanced cancer patients which has sel-
dom been addressed in the literature. It has been shown
that improvement in metastatic bone pain will similarly
improve functional interference as a result of this pain [11].
The BPI is a validated and reliable tool used to assess
pain and the functional interference in patients with bone
metastases; however, its validity has not been conﬁrmed
in telephone use. It had previously been reported that
those experiencing lower body pain have higher levels
of functional interference than those with upper body
pain [11]. In this analysis, we found that after treatment
with conventional radiotherapy, both groups of patients
have similar levels of functional interference. Further, we
validate the BPI through telephone for patients with bone
metastases.
Thefactthatinterferencelevelsareworseinlowerskeletal
pain patients prior to radiotherapy suggests that in general
people exhibiting lower body pain will have more functional
interference than those with upper body pain, not only
inclusive to patients with bone metastases pain. Studies,
however, have suggested that there is an inherent diﬀerence
among pain interference between cancer and noncancer
patients [21] meaning that even if data existed for this
topic in noncancer patients, it might be inappropriate to
compare the results. Overall, our ﬁndings suggest that rapid
management of pain stemming from bone metastases is
crucialto reducefunctional interference and improve quality
of life, especially in those with pain in the lower skeleton.
Radiotherapy reduces functional interference as a resultPain Research and Treatment 7
Table 5: Model-ﬁt statistics for three-factor analysis and improvement after sleep removal at weeks 4, 8, and 12.
Model Modiﬁcation
Goodness of ﬁt
index
(adjusted)
Chi-square
(df)
RMSEA
(upper CL)
Comparative
ﬁt index
Nonnormed
ﬁt index
Model ﬁt statistics at week 4
3 factors: pain, activity
and aﬀect
Covary error terms of average-pain-
current pain, mood-relations 0.95 46.8 (27) 0.07 (0.10) 0.98 0.97
3 factors: pain, activity
and aﬀect
Drop sleep: covary error terms of
average pain-current pain, mood-
relations
0.98 26.1(19) 0.05 (0.09) 0.99 0.99
Model ﬁt statistics at week 8
3 factors: pain, activity
and aﬀect
Covary error terms of average-pain-
current pain, mood-relations 0.95 35.6 (27) 0.05 (0.09) 0.99 0.98
3 factors: pain, activity
and aﬀect
Drop sleep; covary error terms of
average-pain-current pain, mood-
relations
0.96 26.8(19) 0.06 (0.10) 0.99 0.98
Model ﬁt statistics at week 12
3 factors: pain, activity
and aﬀect
Covary error terms of average-pain-
current pain, mood-relations 0.92 46.7 (27) 0.08 (0.12) 0.97 0.95
3 factors: pain, activity
and aﬀect
Drop sleep; covary error terms of
average-pain-current pain, mood-
relations
0.94 33.5(19) 0.08 (0.13) 0.98 0.96
Acceptable model ﬁt Perfect ﬁt = 1 Smaller value RMSEA < 0.10 >0.90 >0.90
Similarly,model ﬁt statisticswere all improved after dropping sleep, at all time periods for two-factor analysis.
Table 6: Week 4 factor loading and associate statistic analysis.
BPI items Two subscales Three subscales
Factor loading R-squared t-statistic Factor loading R-squared t-statistic
Composite reliability pain factor 0.85 Composite reliability pain factor 0.82
Worst pain 0.83 0.73 17.2 0.81 0.73 16.9
Average pain 0.86 0.81 19.2 0.82 0.81 18.7
Current pain 0.73 0.62 14.8 0.71 0.62 14.5
Composite reliability interference factor 0.86 Composite reliability activity factor 0.81
General activity 0.79 0.72 18.5 0.82 0.76 18.0
Walking ability 0.71 0.61 15.1 0.72 0.62 14.5
Normal work 0.72 0.65 16.2 0.75 0.69 16.1
Composite reliability aﬀect factor 0.76
Mood 0.70 0.60 14.7 0.75 0.70 16.7
Enjoyment of life 0.70 0.65 16.3 0.73 0.66 15.8
Relations 0.65 0.48 11.8 0.68 0.57 13.6
Correlation pain-interference: 0.72 Correlation pain-activity: 0.73
Correlation pain-aﬀect: 0.67
Correlation activity-aﬀect: 0.88
It is shown here that the correlation between the subsections of the BPI (in both two- and three- factor analyses) is relatively high. This same result isf o u n d
in week 8 and week 12. In all cases,activity and aﬀect demonstrate a stronger correlation, suggesting the same latent variable.
of pain regardless of location and shrinks the diﬀerence
in functional interference between upper and lower body
metastatic bone pain such that it is not signiﬁcant.
The BPI has been used in numerous studies via tele-
phone, to assess a patient’s response to treatment. Although
the questions remained the same whether asking a patient
across the phone or in person, the diﬀerences in setting
may aﬀect responses and consequently the validity of the
BPI. When comparing the statistical analyses to results of
Wu et al., who validated the BPI in patients with bone8 Pain Research and Treatment
metastases physically in clinic with the same methods
[11], the similar high construct validity and high levels of
correlation within the subscales of the BPI demonstrate its
validity for use over the telephone. This modality should be
recommended when following patients towards the end of
life,asitreducestheburdencausedbynumerousclinicvisits.
The sleep item of BPI contributes little to both the
activity or aﬀect subscales of three-factor analysis and
interference in general in the two-factor analysis. Previous
papers have also noted this diﬀerence when conducting an
analysis of the BPI [11, 22–24]. The lack of correlation in
these subgroups is surprising in this highly symptomatic
population. Two factors contributing to this could have been
due to the side eﬀects of medications (especially the greater
levels of opioids taken by cancer patients) and the patient
adjustingtoreducepaininterference onsleep(i.e.,turningto
sleep on one’s side). The complex nature of the relationship
between pain and sleep should be explored further.
A further point of research would be to test the cor-
relation of the BPI with other musculoskeletal functional
scales, such as theWestern Ontario and McMaster University
Osteoarthritis Index (WOMAC) [25] and the Musculoskele-
tal Function Assessment (MFA) [26] questionnaire. This
could assist in conﬁrming our ﬁndings within this popula-
tion. Another limitation within our setting was the fact that
the most commonly missed item of the BPI was “normal
work”. The majority of people missing this item were elderly
patients with decreased performance status. This population
m a yv i e wt h e m s e l v e sa sn ol o n g e rb e i n gc a p a b l eo fd o i n g
normal work and feel they are not required to answer
this question. As a result, these patients might not have
been represented suﬃciently in our population. Although
expected in this population, a ﬁnal limitation would be the
high rates of attrition. Towards the end of the follow-up
period especially, our results may reﬂect the patients with
higher performance status.
The BPI is a valid and reliable tool for use across the
telephoneand should be the preferred mode ofcontact when
following up with advanced cancer patients. CFA of the BPI
demonstrates validity with both the two- and three-factor
models; however, the latter is preferred as fewer covariance
termsareneededtoﬁtthemodelanditsatisﬁes anadditional
IMMPACT factor. Patients with lower skeletal pain resulting
from bone metastases should receive prompt treatment to
reducetheirfunctionalinterferenceandimprovetheiroverall
qualityoflife. The preferred modality for following palliative
patients with quality-of-life assessments should be via the
telephone as it reduces the travelling burden associated with
multiple visits to a health care setting.
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